[0007] WO2007/0611434 described pharmaceutical compositions of intranasal exenatide using similar formulation technologies in WO2007/146488, plus a dipeptidyl aminopeptidase (DPP) IV inhibitor to minimize enzymatic degradation of exenatide
By working at the biological levelreducing appetite, extending fullness, quieting food cravingsit makes maintaining a caloric deficit feel manageable instead of grueling
doi: 10.1097/j.pain.0000000000001117
However, semaglutide-mediated potentiation of insulin secretion was only detected ex vivo , and does not explain circulating insulin levels in response to an oral glucose tolerance test (Figure 1D-E)
To minimize this risk, try eating smaller, more frequent meals throughout the day
Normal (sterile) saline can reconstitute semaglutide, but it does not prevent bacterial growth